Several clinical studies in HCV-induced vasculitis [78], GvHD [79], and type 1 diabetes have reported that low dose IL-2 therapy is safe, expands Treg frequency, and improves their functional capacity [80, 81]. Here, IL2 is linked to type 1 diabetes mellitus.